LUKAIR montelukast (as sodium) 10 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lukair montelukast (as sodium) 10 mg film-coated tablet blister pack

organon pharma pty ltd - montelukast sodium, quantity: 10.4 mg (equivalent: montelukast, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; hyprolose; hypromellose; titanium dioxide; iron oxide red; iron oxide yellow; carnauba wax - prophylaxis and treatment of chronic asthma in adults and children two years of age and older. symptomatic treatment of seasonal allergic rhinitis

LUKAFAST montelukast (as sodium) 10 mg film coated tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lukafast montelukast (as sodium) 10 mg film coated tablets bottle

strides pharma science pty ltd - montelukast sodium, quantity: 10.38 mg (equivalent: montelukast, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; carnauba wax - prophylaxis and treatment of chronic asthma in adults 15 years of age and older. ,symptomatic treatment of seasonal allergic rhinitis.

Nortriptyline 10mg film-coated tablets Malta - English - Medicines Authority

nortriptyline 10mg film-coated tablets

pinewood laboratories ltd ballymacarbry, clonmel, co. tipperary, ireland - nortriptyline hydrochloride - film-coated tablet - nortriptyline hydrochloride 10 mg - psychoanaleptics

EXEMESTANE TEVA 25 MG Israel - English - Ministry of Health

exemestane teva 25 mg

abic marketing ltd, israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

CLOBEMIX moclobemide 300 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

clobemix moclobemide 300 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - moclobemide, quantity: 300 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate; povidone; magnesium stearate; hypromellose; microcrystalline cellulose; peg-8 stearate; titanium dioxide; propylene glycol; purified water - treatment of major depression.

CLOBEMIX moclobemide 150 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

clobemix moclobemide 150 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - moclobemide, quantity: 150 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate; povidone; magnesium stearate; hypromellose; microcrystalline cellulose; peg-8 stearate; titanium dioxide; propylene glycol; purified water; iron oxide yellow - treatment of major depression.

XADAGO safinamide (as mesilate) 50 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xadago safinamide (as mesilate) 50 mg film-coated tablet blister pack

seqirus pty ltd - safinamide mesilate, quantity: 65.88 mg (equivalent: safinamide, qty 50 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

XADAGO safinamide (as mesilate) 100 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xadago safinamide (as mesilate) 100 mg film-coated tablet blister pack

seqirus pty ltd - safinamide mesilate, quantity: 131.76 mg (equivalent: safinamide, qty 100 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; crospovidone; colour; hypromellose; macrogol 6000 - xadago is indicated for the treatment of adult patients with fluctuating idiopathic parkinson?s disease (pd) as add-on therapy to a regimen that includes levodopa (l-dopa)

Aldomet 250 mg Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

aldomet 250 mg film-coated tablets

aspen pharma trading limited - methyldopa - film-coated tablet - 250 milligram(s) - methyldopa; methyldopa (levorotatory)

Aldomet 500 mg Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

aldomet 500 mg film-coated tablets

aspen pharma trading limited - methyldopa - film-coated tablet - 500  milligram(s) - methyldopa; methyldopa (levorotatory)